Home > Investors
2018 News and Events
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
02/21/18The Medicines Company Reports Fourth-Quarter and Full-Year 2017 Business and Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 21, 2018-- The Medicines Company (NASDAQ:MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2017. “We have successfully executed our strategic action plan for 2017 by divesting our non-core assets, restructuring our business to focus on inclisiran, and initiating the inclisiran Phase 3 ORION program – recently completing target enrollment ahead of schedule in ... 
Printer Friendly Version
02/20/18The Medicines Company Reaches Enrollment Target for ORION-9 Ahead of Schedule
ORION-9, a Phase III confirmatory clinical trial in heterozygous familial hypercholesterolemia patients randomized more than 400 patients in 10 weeks – 14 weeks ahead of schedule PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 20, 2018-- The Medicines Company (NASDAQ: MDCO) today announced that the target of 400 patients randomized in the ORION-9 trial has been exceeded in 10 weeks – considerably ahead of its anticipated recruitment goal of 24 ... 
Printer Friendly Version
02/14/18The Medicines Company to Host Conference Call and Webcast Discussing Fourth-Quarter and Full-Year 2017 Financial Results
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 14, 2018-- The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Wednesday, February 21, 2018, at 8:30 a.m., Eastern Time, to discuss fourth-quarter and full-year 2017 financial results and operational developments. The conference call may be accessed by telephone as follows:   U.S./Canada: ... 
Printer Friendly Version
02/08/18The Medicines Company to Participate in the Leerink Partners 7th Annual Global Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Feb. 8, 2018-- The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018, in New York City. Clive Meanwell, M.D., Ph.D., Chief Executive Officer, will participate in a fireside chat at 9:00 a.m., Eastern Time. A live audio webcast will be available in the “Investors-Events/Presentations” sect... 
Printer Friendly Version
01/25/18Inclisiran’s First Pivotal Trial Achieves Target Enrollment Ahead of Schedule
– ORION-11, a Phase III confirmatory clinical trial randomized more than 1,500 patients in 11 weeks – FDA grants Orphan Drug Designation to inclisiran for the treatment of homozygous familial hypercholesterolemia (HoFH) – Following encouraging Phase II data, a Phase III clinical trial of inclisiran in HoFH set to begin in 2018 – PARSIPPANY, N.J. – January 25, 2018 – The Medicines Company (NASDAQ: MDCO) today announced that the target of 1,500 patients randomized in the ORION-11 t... 
Printer Friendly Version
01/08/18The Medicines Company Announces Closing of Divestiture of Infectious Disease Business Unit to Melinta Therapeutics
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 8, 2018-- The Medicines Company (NASDAQ:MDCO) today announced the closing of the sale of its infectious disease business unit to Melinta Therapeutics, Inc. (NASDAQ: MLNT) for consideration consisting of $215 million of guaranteed cash, approximately 3.3 million shares of Melinta common stock, tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin® IV, and the assumpti... 
Printer Friendly Version
01/03/18The Medicines Company to Present at the 36th Annual J. P. Morgan Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jan. 3, 2018-- The Medicines Company (NASDAQ:MDCO) today announced that its Chief Executive Officer, Clive Meanwell, M.D., Ph.D., will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018, at 8:30 a.m., Pacific Time, at The Westin St. Francis in San Francisco, CA. A Q&A breakout session will immediately follow the presentation at 9:00 a.m., Pacific Time. A live audio... 
Printer Friendly Version